Evidence map›Paper›PMID 29664235›Full record

ArticleJournal of cellular and molecular medicine2018

miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.

Demin Jiao, Jun Chen, Yu Li, Xiali Tang, Jian Wang, Wei Xu, Jia Song, You Li, Huimin Tao, Qingyong Chen

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 87 citations in OpenAlex.

  1. Targeting the NF-κB pathway represents a potential strategy to attenuate HGF-induced resistance to KRAS G12C inhibitors in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The important role of miR-1-3p in cancers.Journal of translational medicine · 2023
    Review
  12. Review
  13. Article
  14. Chinese herbal medicines · 2022
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Demin JiaoDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Jun ChenDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Yu LiDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Xiali TangDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Jian WangDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Wei XuDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Jia SongDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
You LiDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Huimin TaoDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.
Qingyong ChenDepartment of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, China.ORCID 0000-0002-8926-6395
117th Hospital of People's Liberation Army · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocyte growth factor (HGF) overexpression is an important mechanism in acquired epidermal growth factor receptor (EGFR) kinase inhibitor gefitinib resistance in lung cancers with EGFR activating mutations. MiR-1-3p and miR-206 act as suppressors in lung cancer proliferation and metastasis. However, whether miR-1-3p and miR-206 can overcome HGF-induced gefitinib resistance in EGFR mutant lung cancer is not clear. In this study, we showed that miR-1-3p and miR-206 restored the sensitivities of lung cancer cells PC-9 and HCC-827 to gefitinib in present of HGF. For the mechanisms, we demonstrated that both miR-1-3p and miR-206 directly target HGF receptor c-Met in lung cancer. Knockdown of c-Met mimicked the effects of miR-1-3p and miR-206 transfections Meanwhile, c-Met overexpression attenuated the effects of miR-1-3p and miR-206 in HGF-induced gefitinib resistance of lung cancers. Furthermore, we showed that miR-1-3p and miR-206 inhibited c-Met downstream Akt and Erk pathway and blocked HGF-induced epithelial-mesenchymal transition (EMT). Finally, we demonstrated that miR-1-3p and miR-206 can increase gefitinib sensitivity in xenograft mouse models in vivo. Our study for the first time indicated the new function of miR-1-3p and miR-206 in overcoming HGF-induced gefitinib resistance in EGFR mutant lung cancer cell.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCell Line, TumorDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsGefitinibGene Expression Regulation, NeoplasticHepatocyte Growth FactorHumansLiver NeoplasmsMaleMice, Inbred BALB CMicroRNAsProto-Oncogene Proteins c-metAntineoplastic AgentsEGFR protein, humanErbB ReceptorsGefitinibHepatocyte Growth FactorHGF protein, humanMET protein, humanMicroRNAsMIRN1 microRNA, humanMIRN206 microRNA, humanProto-Oncogene Proteins c-metc-MetEMTgefitinib resistancelung cancermiR-1-3pmiR-206

Identifiers

PMID29664235
PMCPMC6010770
OpenAlexW2799777024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.